Skip to main content
Yabao Pharmaceutical Group Co.,Ltd logo

Yabao Pharmaceutical Group Co.,Ltd — Investor Relations & Filings

Ticker · 600351 ISIN · CNE000001CM5 LEI · 65560071PKRS4UHMVU53 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,362 across all filing types
Latest filing 2023-03-31 Transaction in Own Shar…
Country CN China
Listing Shanghai Stock Exchange 600351

About Yabao Pharmaceutical Group Co.,Ltd

http://www.yabao.com.cn

Yabao Pharmaceutical Group Co.,Ltd. focuses on the research, development, manufacturing, and commercialization of pharmaceutical products. The company maintains a specialized portfolio across therapeutic areas including pediatrics, cardiovascular health, and endocrinology. Key offerings include traditional Chinese medicines, chemical drugs, and innovative transdermal patches, such as the Dinggui Erqi Patch. The organization operates integrated production bases and research facilities dedicated to advancing drug delivery systems and biotechnological applications. Its business model emphasizes the modernization of traditional therapies alongside the development of conventional pharmaceuticals to address diverse clinical needs.

Recent filings

Filing Released Lang Actions
亚宝药业集团股份有限公司关于回购股份事项前十名股东持股情况的公告
Transaction in Own Shares Classification · 95% confidence The document is a public announcement by the board of directors of 亚宝药业集团股份有限公司 regarding the shareholding situation of the top ten shareholders prior to a share repurchase plan. It references a previous announcement about the share repurchase plan and provides detailed shareholding data as of a specific date. The content focuses on shareholding details related to a share buyback, not on financial results, management changes, or voting results. The document length is short (1189 characters) and it is an announcement about shareholding in relation to a share repurchase, which fits the category of Transaction in Own Shares (POS).
2023-03-31 Chinese
亚宝药业集团股份有限公司2023年第一次临时股东大会会议资料
AGM Information Classification · 95% confidence The document is titled as meeting materials for the "2023 First Extraordinary General Meeting" of 亚宝药业集团股份有限公司. It contains detailed meeting agenda, voting procedures, and specific proposals related to a share repurchase plan (buyback) including purpose, method, price, funding, and authorization for the board to execute the buyback. The document is a set of meeting materials for a shareholder meeting, not a report or announcement of results. It is not a full annual or interim report, nor an earnings release. It is not a voting results declaration but the materials for the meeting itself. The content aligns with materials typically provided for shareholder meetings to inform and enable voting on specific proposals, which fits the category AGM Information (AGM-R). The document length is under 5,000 characters, but it is not merely an announcement of a report publication; it is the meeting materials themselves. Therefore, the correct classification is AGM Information (AGM-R).
2023-03-31 Chinese
亚宝药业独立董事关于以集中竞价交易方式回购股份的独立意见
Transaction in Own Shares Classification · 95% confidence The document is an independent opinion from the independent directors of 亚宝药业集团股份有限公司 regarding a share repurchase plan through centralized bidding. It discusses the legality, necessity, and feasibility of the share buyback, referencing relevant laws and regulations. The document does not contain financial statements or detailed financial data but is a formal opinion supporting a share repurchase proposal. This fits the category of a Transaction in Own Shares (POS) filing, which reports on the company's buyback of its own shares.
2023-03-27 Chinese
亚宝药业集团股份有限公司第八届董事会第十一次会议决议公告
Transaction in Own Shares Classification · 95% confidence The document is a board meeting resolution announcement from 亚宝药业集团股份有限公司, detailing decisions made by the board including approval of a share repurchase plan and the calling of an extraordinary general meeting. It references a separate announcement about the share repurchase plan published on the Shanghai Stock Exchange website. The document is short (562 characters) and primarily serves as an official announcement of board decisions rather than a full report or detailed financial disclosure. The key content is about the approval of a share repurchase plan, which aligns with the category for company buying back its own shares. Therefore, the document fits best under the category 'Transaction in Own Shares' (POS).
2023-03-27 Chinese
亚宝药业集团股份有限公司关于召开2023年第一次临时股东大会的通知
Regulatory Filings Classification · 95% confidence The document is a notice about convening the 2023 first extraordinary general meeting of shareholders (临时股东大会) for a company, detailing the meeting date, voting methods, agenda items, and procedural instructions. It includes information about the meeting logistics, voting system, and proxy authorization. There is no financial data, earnings information, or detailed report content. The document is an announcement of a shareholder meeting rather than the meeting materials or results. It is also not a proxy solicitation or voting results announcement, but a formal notice of the meeting itself. Therefore, it fits best into the category of a Regulatory Filing (RNS) as a general regulatory announcement that does not fit other specific categories.
2023-03-27 Chinese
亚宝药业集团股份有限公司关于以集中竞价交易方式回购股份方案的公告
Transaction in Own Shares Classification · 100% confidence The document is a detailed announcement regarding a company's plan to repurchase its own shares through a centralized bidding process. It includes specifics about the repurchase purpose, amount, price, funding source, timeline, and legal compliance. The text explicitly mentions the repurchase of shares to be canceled and reduce registered capital, the board's approval, and the need for shareholder meeting approval. This matches the definition of a Transaction in Own Shares (POS) filing, which covers share buybacks or repurchases. The document is not a full financial report, earnings release, or regulatory filing, but a specific announcement about share repurchase plans.
2023-03-27 Chinese

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.